Clinical Trial

Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-19.
Status change: Not Yet Recruiting → Recruiting 2024-05-03
Trial Details
NCT Number NCT05510323
Lead Sponsor Air Force Military Medical University, China
Conditions Glomerulonephritis, IGA
Enrollment 208 participants
Start Date 2024-02-01
Primary Completion 2025-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2024-05-06